M&A / Deals Novo Nordisk partners OpenAI on R&D “transformation” PharmaphorumSeeking an R D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.M&A / DealsRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Seeking an R D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI. M&A / DealsRead full story Post navigation Previous: Travere Therapeutics gains FDA approval for sparsentan in FSGSNext: Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
